Treatment of Primary Progressive Multiple Sclerosis

 

 Buy Article Permissions and Reprints

Abstract

Primary progressive multiple sclerosis (MS) is primarily a neurodegenerative phenotype of MS. It is characterized by a predominant progressive disease course that largely determines the disability progression rather than the rare early superimposed relapses. Therefore, frustratingly, the immunomodulatory and immunosuppressive approaches have failed to have any meaningful impact on the disability progression in primary-progressive MS. Some benefit can still be obtained in select patients where notable number of superimposed relapses or significant ongoing subclinical magnetic resonance imaging activity may allow for immunomodulatory agents to work. Symptomatic treatment for MS should also not be overlooked in this population for impact on quality of life. Future work will likely focus more on the remyelinating and regenerative strategies to help this group of patients. Unfortunately, the lack of any warning symptoms hampers any future prevention trial in this population. However, inferring from previous studies in secondary progressive MS, a global effort to eliminate initiation of tobacco smoking in teenagers or young adults may also delay the onset of a progressive disease course in MS.

• References

• 1 Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain 2006; 129 (Pt 3) 584-594
  CrossrefPubMedGoogle Scholar
• 2 Tutuncu M, Tang J, Zeid NA , et al. Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis. Mult Scler 2013; 19 (2) 188-198
  CrossrefPubMedGoogle Scholar
• 3 Kappos L, Weinshenker B, Pozzilli C , et al; European (EU-SPMS) Interferon beta-1b in Secondary Progressive Multiple Sclerosis Trial Steering Committee and Independent Advisory Board; North American (NA-SPMS) Interferon beta-1b in Secondary Progressive Multiple Sclerosis Trial Steering Committee and Independent Advisory Board. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology 2004; 63 (10) 1779-1787
  CrossrefPubMedGoogle Scholar
• 4 La Maestra S, Kisby GE, Micale RT , et al. Cigarette smoke induces DNA damage and alters base-excision repair and tau levels in the brain of neonatal mice. Toxicol Sci 2011; 123 (2) 471-479
  CrossrefPubMedGoogle Scholar
• 5 Westlye LT, Walhovd KB, Dale AM , et al. Life-span changes of the human brain white matter: diffusion tensor imaging (DTI) and volumetry. Cereb Cortex 2010; 20 (9) 2055-2068
  CrossrefPubMedGoogle Scholar
• 6 Hasan KM, Kamali A, Abid H, Kramer LA, Fletcher JM, Ewing-Cobbs L. Quantification of the spatiotemporal microstructural organization of the human brain association, projection and commissural pathways across the lifespan using diffusion tensor tractography. Brain Struct Funct 2010; 214 (4) 361-373
  CrossrefPubMedGoogle Scholar
• 7 Healy BC, Ali EN, Guttmann CR , et al. Smoking and disease progression in multiple sclerosis. Arch Neurol 2009; 66 (7) 858-864
  CrossrefPubMedGoogle Scholar
• 8 Wolinsky JS, Narayana PA, O'Connor P , et al; PROMiSe Trial Study Group. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 2007; 61 (1) 14-24
  CrossrefPubMedGoogle Scholar
• 9 Wolinsky JS, Shochat T, Weiss S, Ladkani D. PROMiSe Trial Study Group. Glatiramer acetate treatment in PPMS: why males appear to respond favorably. J Neurol Sci 2009; 286 (1-2) 92-98
  CrossrefPubMedGoogle Scholar
• 10 Kantarci OH, Weinshenker BG. Natural history of multiple sclerosis. Neurol Clin 2005; 23 (1) 17-38 , v
  CrossrefPubMedGoogle Scholar
• 11 Kantarci O, Siva A, Eraksoy M , et al; Turkish Multiple Sclerosis Study Group (TUMSSG). Survival and predictors of disability in Turkish MS patients. Neurology 1998; 51 (3) 765-772
  CrossrefPubMedGoogle Scholar
• 12 Johnson KP, Brooks BR, Cohen JA , et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995; 45 (7) 1268-1276
  CrossrefPubMedGoogle Scholar
• 13 Leary SM, Thompson AJ. Interferon beta-1a in primary progressive multiple sclerosis. J Neurol Sci 2003; 206 (2) 215-216
  CrossrefPubMedGoogle Scholar
• 14 Leary SM, Miller DH, Stevenson VL, Brex PA, Chard DT, Thompson AJ. Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology 2003; 60 (1) 44-51
  CrossrefPubMedGoogle Scholar
• 15 British and Dutch Multiple Sclerosis Azathioprine Trial Group. Double-masked trial of azathioprine in multiple sclerosis. Lancet 1988; 2 (8604) 179-183
  PubMedGoogle Scholar
• 16 Goodkin DE, Rudick RA, VanderBrug Medendorp S , et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995; 37 (1) 30-40
  CrossrefPubMedGoogle Scholar
• 17 Rice GP, Filippi M, Comi G. Cladribine MRI Study Group. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Neurology 2000; 54 (5) 1145-1155
  CrossrefPubMedGoogle Scholar
• 18 Hawker K, O'Connor P, Freedman MS , et al; OLYMPUS trial group. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009; 66 (4) 460-471
  CrossrefPubMedGoogle Scholar
• 19 Ghatak NR, Leshner RT, Price AC, Felton III WL. Remyelination in the human central nervous system. J Neuropathol Exp Neurol 1989; 48 (5) 507-518
  CrossrefPubMedGoogle Scholar
• 20 Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases. Brain 1999; 122 (Pt 12) 2279-2295
  CrossrefPubMedGoogle Scholar
• 21 Miller DJ, Bright JJ, Sriram S, Rodriguez M. Successful treatment of established relapsing experimental autoimmune encephalomyelitis in mice with a monoclonal natural autoantibody. J Neuroimmunol 1997; 75 (1-2) 204-209
  CrossrefPubMedGoogle Scholar
• 22 Murray PD, McGavern DB, Sathornsumetee S, Rodriguez M. Spontaneous remyelination following extensive demyelination is associated with improved neurological function in a viral model of multiple sclerosis. Brain 2001; 124 (Pt 7) 1403-1416
  CrossrefPubMedGoogle Scholar